Rosiglitazone increases high-density lipoprotein cholesterol levels in patients with type 2 diabetes  by Schaefer, Ernst & Gould, Errol
316A ABSTRACTS - Vascular Disease, Hypertension, and Prevention JACC March 19,2003 
Least-square mean % changes in LDL-C and high-density lipoprotein-C (HDL-C) from 
baseline from analysis of variance 
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Conclusion. Fenofibrate significantly reduced small, dense LDL. The mean reduction in 
small LDL (-28.5%) was balanced by an increase in large LDL (+22.7%) explaining the 
lack of change in total LDL. Fenofibrate reduced the smallest LDL (IVb) which has been 
independently linked to arteriographic progression in the Stanford Coronary Risk Inter- 
vention Project. 
Significantly different (pc.002) compared with@)RSV 10 mg, @)RSV 20 mg. @)RSV 40 
mg, @)RSV 80 mg 
676-3 On-Treatment Increments in Serum High-Density 
Lipoprotein Levels Are Associated With Improved 
Survival in Patients With Coronary Heart Disease: An 
Extended Follow-Up of the Bezafibrate Infarction 
Prevention Trial 
llan Goldenberg Uri Goldbourt, Valentina Boyce. Solomon Behar, Henrietta Reicher- 
Conclusions: Across doses, RSV was more effective in lowering LDL-C than AN, SIM, Ernst Schaefer, Errol Gould, Tufts University School of Medicine, Boston, MA, 
and PRA. RSV consistently raised high-density lipoprotein-cholesterol at all doses. GlaxoSmithKline, Collegeville, PA 
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Background: While the primary target for lipid-lowenng therapy is low-density lipopro- 
tein cholesterol, recent guidelines stats that a high-density lipoprotein cholesterol 
(HDLC) level ~40 mg/dL necessitates intervention due to an increased risk of cardiovas- 
cular disease (CVD). The total cholesterol:HDLC ratio is also important for stratifying 
CVD risk. 
Methods: We retrospectively examined the long-term effect of the antidiabetic agent 
rosiglitazone (RSG) on HDLC using subanalyses of data from 269 patients with Type 2 
diabetes who took RSG 8 mgiday for 24 months in open-label extensions of 2 similarly 
designed placebo-controlled double-blind studies. Data were analyzed according to 
baseline HDLC values (<40 or?40 mg/dL) and total cholesterol:HDLC (~5 orz5). 
Results: HDLC concentration continued to increase over 24 months of RSG treatment, 
representing a mean increase from baseline of 25% in the HDLC ~40 mg/dL group and 
10% in the HDLC z40 mg/dL group. For all patients, total cholesterol:HDLC decreased 
from 5.06 to 4.70 over the 24-month RSG treatment period. In patients with total choles- 
terol:HDLC s the mean ratio decreased from 6.25 to 5.60 after 24 months. In patients 
with total cholesterol:HDLC c5 the mean ratio decreased from 3.92 to 3.88 after 24 
months. 
Relss, Heart Institute. Sheba Medical Cernter, Tel Hashomer, Israel 
Background Low serum HDL cholesterol (HDL-C) predicts coronary heart disease 
(CHD). The Bezafibrate Infarction Prevention (BIP) trial was designed to assess the eff- 
cacy of raising HDL-C in CHD patients with HDL-C <45 mg/dL. In this analysis of an 
extended 8.2-year follow-up of the trial we evaluated the association between HDL-C 
modification and all-cause and cardiac mortality. Methods Study patients were random- 
ized to receive either bezafibrate 400 mg daily or placebo. The experience of the 1509 
bezafibrate treated patients, in tertiles of on-treatment increments in the ratio of HDL-C to 
total cholesterol (%HDL-C), was compared with that of the 1517 patients in the placebo 
group, to examine the effect of %HDL-C changes on ail-cause and cardiac mortality. 
Results Over a mean follow-up period of 8.2 years the mortality rate was 15.2% in tne 
placebo group and 13.9% in the bezafibrate group (~~0.33). Bounds for each on-treat- 
ment tertile of %HDL-C change were 1 (-4.8% to +2.2%); 2 (+2.2% to +5.1%); and 3 
(+5.1% to +19.7%). All-cause mortality rates were 17.3% (n=497), 13.4% (n=514), and 
11 .O% (n=498) in tertiles 1, 2 and 3, respectively (p=O.O2). The reduction rn all-cause 
mortality reflected a highly significant decline in the cardiac mortality rate with increasing 
increments in %HDL-C (placebo group - 8.9 %; tertile 1 - 10.9%; tertile 2 5.8%; tertile 3 
5.6%; p=O.O02). Multivariate adjustment for baseline clinical characteristics and lipid 
values confirmed increased %HDL-C levels as an independent predictor of improved sur- 
vival, compared to the placebo group (all-cause mortality: HR= 0.85 [95% Cl 0.65-l ,121 
and 0.69 95% [Cl 0.51-0.931 for tertiles 2 and 3 respectively; cardiac modality: HR= 0.61 
(95% Cl 0.41-0.911 and 0.58 [95% Cl 0.38-0.881 for tetiles 2 and 3 respectively). Tertile 1 
patients exhibited increased all-cause and cardiac mortality hazard (HR= 1.22 [95% Cl 
0.95-I ,581 and 1.30 [95% Cl 0.94-l ,801 respectively), compared to the placebo group. 
Conclusions In CHD patients with HDL-C ~45 mg/dL, successful modification of the 
fraction of total serum cholesterol contained in the HDL moiety with bezafibrate therapy, 
is independently associated with improved long-term survrval. 
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876-4 Fenofibrate Lowers Small Low-Density Lipoprotein With 
No Change in Total Low-Density Lipoprotein 
Cholesterol 
H. Robert Superko, Sherna Madan, David Tonnemacher, Nicolas Chronos, Brenda 
Garrett, Dennis Sheehan, Elaine Raul, Steve Frohwein, Kenneth McGrath, Jr.. American 
Cardiovascular Research Institute, Atlanta, GA, Berkeley HeartLab. Berkeley, CA 
Purpose: Differences in the distribution of 7 LDL subclasses is finked to CAD risk and 
arteriographic outcome. We hypothesized that fenofibrate would have a beneficial effect 
on LDL subclass distribution in normocholesterolemic patients. 
Methods: 50 patients were treated with fenofibrate for dyslipidemia. Fasbng blood was 
analyzed prior to. and a mean of 3.8 months following, fenofibrate treatment (200 mgld). 
Fasting blood was analyzed for triglycerides (TG, mg/dl), total cholesterol (TC). LDLC 
and HDLC by enzymatic methods, 7 LDL and 5 HDL subclasses (%) by S3-Gradient Gel 
Electrophoresis using duplicate measures and internal standards and controls calrbrated 
to analytic ultracentrifugation at the University of California. Data was analyzed using the 
patient as their own control. 
Results: Mean&D baseline values (mg/dl) were: TC 185+_46, LDLC 100132, HDLC 
44.8+12.9. TG ?03+161. Fenofibrate treatment resulted in a sianifrcant reduction in tria- 
lycer~des (-26.6%, p<O.Ol), a significant increase in HDLC (+10.7%, p-zO.001) and no sig- 
nificant change in total or LDLC. The atherogenic small LDL region Illa+b was 
significantly reduced (pcO.02). 
LDL I LDLIla LDL Ilb LDL llla LDL LDL LDL IVb 
lllb IVa 
Baselrne 19.827. 15.3+5. 20.925. 23.8+7. 9.0+5.4 6.3i3.2 5.09.7 
8 3 9 0 
PostFenofibrate 25.228. 20.0+5. 23.025. 17.827. 5.79.8 4.9i2.9 3.5i2.2 
2 4 2 1 
P 0.07 0.004 0.02 0.01 0.02 0.17 0.004 
% Change +27.3 +30.7 +lO.O -25.2 -36.7 -22.2 -30.0 
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876-5 Rosiglitazone Increases High-Density Lipoprotein 
Cholesterol Levels in Patients With Type 2 Diabetes 
Conclusion: RSG improved HDLC and total cholesterol:HDLC ratio over 24 months in 
Type 2 diabetes patients, More marked improvement was shown in patrents at greater 
CVD risk (ie, low HDLC [c40 mg/dL] and high total cholesterol:HDLC [x6]). 
HDLC concentration following treatment with RSG, mgidL 
All patients Baseline HDLC ~40 mgfdL Baseline HDLC 240 mg/dL 
n=269 n=99 n=170 
Baseline 45.3 33.1 52.5 
6 months 50.4 39.2 56.8 
12 months 51.2 39.7 58.1 
18 months 52.1 41.7 58.1 
24 months 51.9 41.3 58.1 
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876-6 C-Reactive Protein Is Reduced During Ezetimibe 
Coadministration With Simvastatin in Patients With 
Primary Hypercholesterolemia 
Philip Saqer, Lorenzo Melani, Leslie Lipka, John Strony, Ramachandran Suresh, Enrico 
Veltri. the Ezetimibe Study Group, Schering-Plough Research Institute, Kenilworth. NJ 
Background: C-reactive protein (CRP), a marker of inflammation, is a novel risk factor 
for CHD; ezetimibe (EZE) co-admimstered with a statin significantly improves the lipid 
profile but its effect on CRP is unknown. 
Methods: EZE coadministered with simvastatin (SIMV) was evaluated in a randomized, 
double-blind, placebo (PBO)-controlled study in 668 patients with primary hypercholes- 
terolemia. After NCEP diet, a drug washout and 4.wk, single-blind, PBO lead-in period, 
oatients with baseline LDL-C 2145 to Q50 ma/d1 and TG ST50 ma/d1 were randomized to 
; of the following administered daily for 12 consecutive wks: EZE;O mg; SIMV 10, 20,40 
or 80 mo: EZE 1Oma + SIMV 10.20.40 or 80ma: or PBO. 
Results: Pooled EZE + SIMV reduced LDL-C from baseline by 49.9% versus pooled 
SIMV alone (36.1%, PcO.01) and co-administration was superior to statin alone at each 
SIMV dose. Overall, median % reductrons in CRP from baseline were almost 2X greater 
with pooled EZE + SIMV versus pooled SIMV alone (-34.8% versus -18.2%, P<O.Ol). 
Median CRP was reduced in pooled EZE + SIMV to 0.180 mg/dL and with SIMV to 0.215 
mg/dL (P=O.O3). CRP reductions by EZE + SlMVlO were comparable to SIMVBO. 
